.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Accenture
Julphar
Deloitte
AstraZeneca
Cerilliant
Baxter
Dow
Johnson and Johnson

Generated: November 18, 2017

DrugPatentWatch Database Preview

ZURAMPIC Drug Profile

« Back to Dashboard

What is the patent landscape for Zurampic, and when can generic versions of Zurampic launch?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and seventy-three patent family members in thirty-eight countries and eleven supplementary protection certificates in nine countries.

The generic ingredient in ZURAMPIC is lesinurad. Two suppliers are listed for this compound. Additional details are available on the lesinurad profile page.

Summary for ZURAMPIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZURAMPIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,552,043N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
7,435,752N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors► Subscribe
8,106,205N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
8,193,234Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,344,012Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,481,581S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
7,947,721S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,946,273S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase► Subscribe
8,633,232Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
7,683,087N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZURAMPIC

Country Document Number Estimated Expiration
China103819419► Subscribe
Hong Kong1172326► Subscribe
Denmark2135608► Subscribe
Argentina069753► Subscribe
Eurasian Patent Organization200901186► Subscribe
Australia2012203172► Subscribe
European Patent Office2217577► Subscribe
Cyprus1112221► Subscribe
New Zealand595035► Subscribe
Israel201546► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZURAMPIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016024Lithuania► SubscribePRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
C0031France► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
169Luxembourg► SubscribePRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2016000060Germany► SubscribePRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
0160027 00203Estonia► SubscribePRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
2016 00034Denmark► SubscribePRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
0825Netherlands► SubscribePRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016024,C2135608Lithuania► SubscribePRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218
/2016Austria► SubscribePRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Mallinckrodt
Citi
US Department of Justice
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
QuintilesIMS
Fish and Richardson
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot